Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This clinical trial studies whether measuring circulating tumor deoxyribonucleic acid (ctDNA) tumor fraction (TF) can be used to help guide the early stopping (discontinuation) of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) in patients with castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Many types of tumors tend to lose cells or release different types of cellular products including their deoxyribonucleic acid, which is referred to as ctDNA, into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for the disease to grow, spread, or get worse or come back after a period of improvement. ctDNA TF is a type of ctDNA measurement. Research has shown ctDNA TF may be a promising way to predict which patients will respond to 177Lu-PSMA-617 treatment. Measuring ctDNA TF may help doctors identify which patients may benefit from changing treatments sooner, which may be an effective way to guide early 177Lu-PSMA-617 treatment discontinuation in patients with metastatic castration-resistant prostate cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyźni w wieku 18 lat i powyżej
- •Potwierdzony rozpoznaniem raka gruczołu krokowego
- •Przerzuty nowotworu widoczne w badaniach obrazowych (scintygrafia kości lub CT)
- •Rak prosty oporny na leczenie hormonalne z wzrastającym poziomem PSA
- •Terapia hormonalna nie działała - wymagane poprzednie leczenie co najmniej jednym lekiem hamującym receptor androgenowy
- •Zdolność do kwalifikacji do leczenia lutetem Lu-177 lub docetakselem
- •Wystarczająco dobre wyniki badań krwi: liczba neutrofili, płytki krwi, hemoglobina
- •Zdolność do współpracy w badaniu i oddawania próbek krwi
✗ Disqualifies
- •Poważne problemy zdrowotne lub zaburzenia psychiatryczne mogące wpłynąć na udział w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 27, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Fred Hutch/University of Washington Cancer Consortium
Seattle, United States
Trial contact
Michael Schweizer, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/28/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.